Fly News Breaks for February 27, 2020
Feb 27, 2020 | 20:18 EDT
Piper Sandler analyst Christopher Raymond keeps his Overweight rating and $8 price target on Rigel Pharmaceuticals after its Q4 results, saying that with the management pre-announcing the Tavalisse revenue and "encouraging metrics" last month, there was little surprise in the release. The analyst notes that he remains positive heading into 2020, with an earlier-line ITP patient Tavalisse uptake serving as a tailwind for the shares.
News For RIGL From the Last 2 Days
There are no results for your query RIGL